Saturday, 20 April 2024
BLIS Technology Ordinary Shares
-
22 January 2018
Blis Technologies Limited Update of the Company Performance.
Third Quarter FY 2018, ending 31 December 2017.
Blis Technologies Limited announces the interim results (unaudited) for the
3rd quarter ending 31 December 2017. Revenue for the quarter was $1.6 m, with
a positive EBITDA of $0.2 m and a small net profit.
The 3rd quarter revenue was 6% up on the previous quarter and similar to the
same period last year.
B
more»
-
Disclosure of ceasing to have substantial holding
Section 279, Financial Markets Conduct Act 2013
Note: This form must be completed in accordance with the instructions at the
end of the form.
To NZX
and
To Blis Technologies Limited
Date this disclosure made: 23 November 2017
Date last disclosure made: 2 February 2017
Date on which substantial holding ceased: 23 November 2017
Substantial product holder(s) giving disclosure
more»
-
Disclosure of beginning to have substantial holding
Section 276, Financial Markets Conduct Act 2013
Note: This form must be completed in accordance with the instructions at the
end of the form.
To NZX
and
To Blis Technologies Limited
Date this disclosure made:23 November 2017
Date on which substantial holding began: 23 November 2017
Substantial product holder(s) giving disclosure
Full name(s): WEN Yi
Summary of substantial
more»
-
22 November 2017
Blis Technologies announces new distribution partner for NZ Pharmacy channel
Blis Technologies is pleased to announce a new agency relationship with
Radiant Health for the promotion of the BLIS portfolio in the Pharmacy
channel.
Radiant Health is one of the leading independent distributors in the NZ
pharmacy channel, covering both prescription and consumer health products.
This new relationship represents a change
more»
-
21 November 2017
BLIS K12 Gains Australian Regulatory Approval
Blis Technologies has received notification from the Australian Therapeutic
Goods Administration, that its probiotic strain Streptococcus salivarius BLIS
K12 has been approved as an active ingredient for Listed Complementary
Medicines.
CEO Brian Watson said, "This approval will allow us to enter the Australian
market with our finished product portfolio based on BLIS K12.
more»
-
Blis Technologies Limited- Half Yearly Reports to 30 September 2017.
Brian Watson
Chief Executive
20 September 2017
End CA:00310603 For:BLT Type:INTERIM Time:2017-11-20 08:32:27
more»
-
09 November 2017
Announcement: New Chief Financial Officer Appointment
Blis Technologies is pleased to announce the appointment of Richard Wingham
to the role of Chief Financial Officer. Mr Wingham will lead the overall
financial function for the company as well as being a key member of the
leadership team.
Mr Wigham comes to the role with a wealth of experience in financial
leadership positions across a range of industries including
more»
-
Please see attached an Ongoing Disclosure Notice for Julie Anne Curphey of
Blis Technologies Limited ("BLT").
End CA:00309538 For:BLT Type:SHINTR Time:2017-10-31 16:55:06
more»
-
27th October 2017
Blis Technologies Limited- Update of the company performance.
The Company is currently preparing its preliminary announcement and half year
report for the six months ending 30 September 2017 (unaudited) (HY18). These
will be available by 23 November 2017.
These results will show a reduction in trading revenue for HY18 of 46%
compared with the same period last year (HY18 $2.069 m compared with HY17
$3.836 m). In HY1
more»
-
Please see attached an Ongoing Disclosure Notice for Julie Anne Curphey of
Blis Technologies Limited ("BLT")
End CA:00306210 For:BLT Type:SHINTR Time:2017-08-28 08:56:28
more»
| Code | Last | Change |
|---|
| COMP | 10,321 | 328 |  | 3.08% |
| DJI | 29,635 | 404 | | 1.34% |
| SP500 | 3,583 | 87 | | 2.37% |
| DAX | 12,438 | 82 |  | 0.67% |
| FTSE | 7,488 | 5 | | 0.07% |
| NI225 | 22,420 | 408 | | 1.86% |
| TWI | 67.27 | 0.00 |  | 0.00% |